Nurix Therapeutics Ownership
| NRIX Stock | USD 21.82 0.23 1.04% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 62.4 M | Current Value 72.8 M | Avarage Shares Outstanding 44.1 M | Quarterly Volatility 14.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Nurix |
Nurix Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The book value of Nurix Therapeutics was now reported as 5.62. The company recorded a loss per share of 2.9. Nurix Therapeutics had not issued any dividends in recent years. Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. Nurix Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people. To find out more about Nurix Therapeutics contact the company at 415 660 5320 or learn more at https://www.nurixtx.com.Besides selling stocks to institutional investors, Nurix Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Nurix Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Nurix Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Nurix Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Nurix Therapeutics Insider Trades History
Only 1.45% of Nurix Therapeutics are currently held by insiders. Unlike Nurix Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Nurix Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Nurix Therapeutics' insider trades
Nurix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Nurix Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nurix Therapeutics backward and forwards among themselves. Nurix Therapeutics' institutional investor refers to the entity that pools money to purchase Nurix Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Soleus Capital Management, L.p. | 2024-06-30 | 2.1 M | Commodore Capital Lp | 2024-09-30 | 1.6 M | Citadel Advisors Llc | 2024-09-30 | 1.5 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Driehaus Capital Management Llc | 2024-06-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Candriam Luxembourg S.c.a. | 2024-06-30 | 1.2 M | Deutsche Bank Ag | 2024-06-30 | 1 M | Nuveen Asset Management, Llc | 2024-06-30 | 981.2 K | Blackrock Inc | 2024-06-30 | 6.8 M | Redmile Group, Llc | 2024-09-30 | 4.3 M |
Nurix Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nurix Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nurix Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nurix Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nurix Therapeutics Outstanding Bonds
Nurix Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nurix Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nurix bonds can be classified according to their maturity, which is the date when Nurix Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| US67080LAA35 Corp BondUS67080LAA35 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Nurix Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 4th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.